Tag: oncolytic adenovirus market share

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Oncolytic Adenovirus Market Expansion From $143.56 Billion In 2026 To $195.85 Billion In 2030

The market for oncolytic adenoviruses has experienced robust expansion recently. Projections indicate a notable increase from $132.49 billion in 2025 to $143.57 billion in 2026, reflecting a compound annual growth rate of 8.4%. This expansion during the historical period is underpinned by factors such as the emergence of initial adenovirus-based treatment options, a rise in melanoma and prostate cancer diagnoses, increased funding for oncolytic virus studies, early acceptance by cancer research facilities, and enhanced partnerships between biotechnology firms and academic organizations.

The market for oncolytic adenoviruses is projected for substantial expansion in the upcoming years, with forecasts indicating a reach of $195.85 billion by the year 2030, driven by a compound annual growth rate (CAGR) of 8.1%. This projected growth over the forecast period is underpinned by several key factors, including a heightened demand for sophisticated engineered adenovirus treatments, their increasing application in managing breast, ovarian, and lung cancers, a greater involvement from biotechnology firms, elevated investment in clinical trials and research and development activities, and the enhanced capabilities of hospitals and research institutions in the field of gene therapy. Significant trends anticipated during this forecast period involve the growing integration of artificial intelligence and big data analytics within oncolytic virus research, the expanding use of genomics and precision medicine approaches in the engineering of these viruses, the increased deployment of digital platforms for the oversight of clinical trials, a rise in automated processes for viral production and quality assurance, and the more frequent utilization of the Internet of Things for the monitoring of virus storage and distribution systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

Oncolytic Adenovirus Market Development Factors: Which Trends Are Supporting Demand?

The global demand for oncolytic adenovirus is anticipated to surge due to the escalating prevalence of cancer. Cancer, defined by the uncontrolled proliferation and dissemination of cells, is becoming more common owing to factors such as an aging demographic, lifestyle choices, environmental influences, inherited predispositions, and enhanced diagnostic capabilities. Oncolytic adenoviruses present a promising therapeutic strategy by selectively seeking out and destroying cancerous cells, thereby addressing the increasing burden of this disease. For illustration, data from the National Cancer Institute indicated approximately 20 million new cancer diagnoses and 9.7 million fatalities globally in May 2024, with predictions suggesting these figures could reach 29.9 million cases and 15.3 million deaths by 2040. Additionally, Australian Bureau of Statistics figures from 2023 revealed that 1.8% of Australians had cancer, with a slightly higher incidence in males (2.1%) compared to females (1.6%), particularly among the elderly aged 75 and above. Consequently, the rising rates of cancer are a significant catalyst for expansion within the oncolytic adenovirus market.

The expanding embrace of personalized medicine is poised to accelerate the expansion of the oncolytic adenovirus sector. Personalized medicine involves customizing medical interventions for individual patients, taking into account their unique genetic makeup, biomarker profiles, phenotypic traits, or psychosocial factors, with the aim of optimizing therapeutic effectiveness while reducing adverse effects. This trend is fueled by progress in comprehending the intricacies of tumor biology and the development of therapies designed to target particular genetic alterations or biomarkers, leading to improved patient outcomes and enhanced safety. Oncolytic adenoviruses are particularly well-suited to this paradigm, facilitating the creation of highly specific viral treatments designed to selectively target and eliminate malignant cells. As an example, the Personalized Medicine Coalition reported in February 2024 that the U.S. FDA authorized 26 novel personalized treatments in 2023, encompassing 20 new molecular entities and 6 therapies based on gene or cell modification. Accordingly, the increasing adoption of personalized medicine serves as a key driver for the growth trajectory of the oncolytic adenovirus market.

Oncolytic Adenovirus Market Segmentation: How Is The Market Structured Across Key Categories?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

Oncolytic Adenovirus Market Transformation Trends: Which Innovations Are Driving Change?

Leading players within the oncolytic adenovirus sector are prioritizing the development of combined treatment approaches, exemplified by VCN-01. this innovative therapy merges oncolytic virotherapy with conventional chemotherapy, aiming to refine tumor-specific delivery and amplify the overall effectiveness of treatment. VCN-01 functions as a genetically modified oncolytic adenovirus designed for the precise targeting and elimination of cancerous cells, concurrently boosting the efficacy of chemotherapy regimens. A noteworthy development occurred in May 2024 when Theriva Biologics, a clinical-stage immuno-oncology firm headquartered in the United States, reported that the U.S. Food and Drug Administration (FDA) bestowed Fast Track Designation (FTD) upon their principal candidate, VCN-01. This designation is specifically for VCN-01 when administered alongside gemcitabine and nab-paclitaxel to address metastatic pancreatic adenocarcinoma. Essentially, VCN-01 is an oncolytic adenovirus that seeks out and multiplies within tumor cells, contributing to the degradation of the tumor’s stromal environment, a significant impediment to successful cancer therapy.

Oncolytic Adenovirus Market Competitive Landscape And Leading Companies

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Access The Complete Oncolytic Adenovirus Market Report:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

Oncolytic Adenovirus Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the oncolytic adenovirus market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Oncolytic Adenovirus Market Between 2026 And 2030?

The oncolytic adenovirus market has experienced significant growth over recent years. This market is projected to expand from $132.49 billion in 2025 to reach $143.57 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. Factors contributing to its historical growth include the emergence of first-generation adenovirus-based therapies, the rising incidence of melanoma and prostate cancer, increased investment in oncolytic virus research, initial uptake by cancer research institutes, and expanding partnerships between biotechnology firms and academic institutions.

The oncolytic adenovirus market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $195.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This projected growth is driven by factors such as an escalating demand for engineered adenovirus therapies, their expanding use in treating breast, ovarian, and lung cancers, increased involvement from biotechnology firms, heightened investment in clinical trials and research and development (R&D), and the broadening capabilities of hospitals and research institutes in gene therapy. Key trends foreseen during this period encompass the growing integration of AI and big data in oncolytic virus research, the expanding application of genomics and precision medicine in virus engineering, a wider embrace of digital platforms for overseeing clinical trials, enhanced automation in the production and quality control of viruses, and the proliferation of IoT-enabled systems for monitoring virus storage and distribution.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Major Growth Factors Are Impacting The Oncolytic Adenovirus Market?

The escalating prevalence of cancer is anticipated to fuel the expansion of the oncolytic adenovirus market. Cancer, a condition marked by uncontrolled cellular multiplication and metastasis throughout the body, is seeing an uptick in its occurrence due to factors such as an aging global populace, various lifestyle choices, environmental exposures, inherited predispositions, and advancements in diagnostic methods. Oncolytic adenoviruses offer a promising therapeutic avenue by specifically targeting and eradicating cancerous cells. Supporting this trend, reports from the National Cancer Institute (NCI), a US-based government agency, indicated nearly 20 million new cancer cases and 9.7 million deaths globally in May 2024, with forecasts for 2040 suggesting an increase to 29.9 million cases and 15.3 million deaths. Additionally, data from 2023 by the Australian Bureau of Statistics, an Australia-based government agency, revealed that 1.8% of Australians lived with cancer, with a higher proportion among males (2.1%) compared to females (1.6%), particularly those aged 75 and over. Consequently, the rising incidence of cancer is a key driver for the growth of the oncolytic adenovirus market.

How Are Different Segment Groups Identified Within The Oncolytic Adenovirus Market?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

Which Trends Are Shaping The Oncolytic Adenovirus Market Landscape?

Leading companies in the oncology nutrition market are focused on creating innovative solutions, such as specialized nutrition for cancer patients, to improve treatment outcomes, support immune function, manage treatment-related side effects, and enhance the overall quality of life during and after cancer therapy. Nutrition for cancer patients involves specialized dietary plans and nutritional interventions designed to meet the unique needs of individuals undergoing cancer treatment. For example, in June 2024, AEACAP, the Spain-based Patients Support Association, introduced a new nutrition series intended to support cancer patients and their caregivers. This initiative features a collection of videos released every two weeks, presented by a specialized nutritionist, aiming to provide essential information on diet and nutrition during and after cancer treatment, thereby highlighting the critical role that proper nutrition plays in enhancing treatment outcomes and overall quality of life for those affected by cancer.

Who Are The Prominent Players Across The Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Access The Complete Oncolytic Adenovirus Market Report:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

What Is The Largest Regional Market In The Oncolytic Adenovirus Market?

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oncolytic Adenovirus Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company

Companion Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Clinical Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Oncolytic Adenovirus Market Grow Between 2026 And 2030?

The oncolytic adenovirus market has demonstrated robust expansion over recent years. Its valuation is set to climb from $132.49 billion in 2025 to $143.57 billion in 2026, with a compound annual growth rate (CAGR) of 8.4%. This historical growth can be linked to the progression of first-generation adenovirus-based therapies, the rising incidence of melanoma and prostate cancer, increased funding for oncolytic virus research, initial implementation by cancer research institutes, and enhanced partnerships between biotechnology firms and academic entities.

The oncolytic adenovirus market is anticipated to experience substantial growth over the coming years, with projections indicating an expansion to $195.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. This projected increase is driven by factors such as the escalating demand for engineered adenovirus therapies, their increased use in treating breast, ovarian, and lung cancers, a rise in biotechnology company involvement, greater funding for clinical trials and research and development efforts, and the enhanced capabilities of hospitals and research institutes in gene therapy. Key trends influencing the market during this forecast period include the expanding integration of AI and big data in oncolytic virus research, the growing application of genomics and precision medicine in virus engineering, an increased reliance on digital platforms for overseeing clinical trials, heightened automation in viral production and quality control, and the deployment of IoT-enabled systems for monitoring virus storage and distribution.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Significant Factors Are Influencing The Oncolytic Adenovirus Market Expansion?

The growing occurrence of cancer is projected to drive expansion within the oncolytic adenovirus market in the future. Cancer is defined as an illness marked by unchecked cell proliferation and its dissemination throughout the body. This rising prevalence of cancer stems from factors such as aging demographics, lifestyle choices, exposure to environmental elements, genetic susceptibilities, and enhanced diagnostic capabilities. Oncolytic adenovirus specifically targets and eliminates cancer cells, presenting a promising method for addressing the escalating rates of cancer. For example, reports from the US government’s National Cancer Institute (NCI) in May 2024 indicated almost 20 million new cancer cases and 9.7 million global deaths, with forecasts predicting an increase to 29.9 million cases and 15.3 million deaths by 2040. Moreover, data from the Australian Bureau of Statistics in 2023 showed that 1.8% of Australians suffered from cancer, with males (2.1%) being marginally more impacted than females (1.6%), particularly among individuals aged 75 and over. Consequently, the increasing incidence of cancer is stimulating growth in the oncolytic adenovirus market.

Which Segment Categories Are Included In The Oncolytic Adenovirus Market Segment Analysis?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

What Trends Are Affecting The Direction Of The Oncolytic Adenovirus Market?

Major companies within the oncolytic adenovirus market are prioritizing combination therapies, such as VCN-01, which merges oncolytic virotherapy with chemotherapy to improve tumor targeting and therapeutic outcomes. VCN-01 is an oncolytic adenovirus crafted to selectively infect and eliminate cancer cells, simultaneously bolstering the efficacy of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, revealed that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation applies to VCN-01 when administered in combination with gemcitabine and nab-paclitaxel for treating metastatic pancreatic adenocarcinoma. VCN-01 functions as an oncolytic adenovirus that targets and replicates within tumor cells, assisting in the degradation of the tumor stroma, a significant impediment to effective cancer treatment.

Who Are The Active Companies Shaping The Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Get The Full Oncolytic Adenovirus Market Report:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

Which Region Leads The Oncolytic Adenovirus Market In Terms Of Market Share?

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oncolytic Adenovirus Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company

Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Cancer Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Clinical Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Oncolytic Adenovirus Market Between 2026 And 2030?

The oncolytic adenovirus market has demonstrated significant growth in its size over recent years. It is projected to expand from $132.49 billion in 2025 to $143.57 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. This historical expansion can be linked to the emergence of first-generation adenovirus-based therapies, the increasing occurrence of melanoma and prostate cancer, a surge in investment in oncolytic virus research, prompt adoption by cancer research institutes, and strengthening collaborations between biotechnology and academic institutions.

The oncolytic adenovirus market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $195.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this anticipated growth include an escalating demand for engineered adenovirus therapies, their expanding use in treating breast, ovarian, and lung cancers, increased involvement from biotechnology firms, a surge in funding directed towards clinical trials and research and development, and the broadening capacities of hospitals and research institutions in gene therapy. Key trends expected during the forecast timeframe encompass the increasing integration of AI and big data in oncolytic virus research, wider application of genomics and precision medicine in virus engineering, a rise in the utilization of digital platforms for overseeing clinical trials, enhanced automation in the production and quality control of viral agents, and improved IoT-enabled systems for monitoring virus storage and distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Major Drivers Are Influencing Demand In The Oncolytic Adenovirus Market?

The rising occurrence of cancer is projected to fuel the expansion of the oncolytic adenovirus market in the future. Cancer, defined by the unchecked proliferation of cells and their dissemination throughout the body, presents a significant health challenge. This surge in cancer cases stems from an aging global demographic, various lifestyle influences, environmental exposures, inherited genetic susceptibilities, and enhanced diagnostic capabilities. Oncolytic adenovirus offers a promising therapeutic strategy by specifically targeting and eradicating cancer cells, thereby addressing the growing incidence of the disease. For example, data from May 2024 released by the National Cancer Institute (NCI), a US government agency, indicated nearly 20 million new cancer cases and 9.7 million deaths globally, with forecasts for 2040 suggesting an increase to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australian government body, reported that 1.8% of Australians were affected by cancer, with males (2.1%) showing a slightly higher prevalence than females (1.6%), particularly among individuals aged 75 and over. Consequently, the expanding prevalence of cancer is a key factor propelling the oncolytic adenovirus market’s growth.

Which Market Segments Are Examined In The Oncolytic Adenovirus Market Study?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

How Are Trends Transforming The Oncolytic Adenovirus Market Landscape?

Leading entities within the oncolytic adenovirus sector are prioritizing integrated therapeutic approaches, exemplified by VCN-01, where oncolytic virotherapy is paired with chemotherapy to achieve better tumor targeting and elevate treatment effectiveness. VCN-01 is an oncolytic adenovirus designed for selective infection and destruction of malignant cells, concurrently boosting the efficacy of chemotherapy. A notable example occurred in May 2024, when Theriva Biologics, a US-based clinical-stage immuno-oncology company, revealed that the U.S. Food and Drug Administration (FDA) had bestowed Fast Track Designation (FTD) upon its lead candidate, VCN-01. The FTD is applicable to VCN-01 when employed synergistically with gemcitabine and nab-paclitaxel for addressing metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that specifically aims for and multiplies inside tumor cells, assisting in the degradation of the tumor stroma, which represents a significant impediment to successful cancer therapy.

Who Are The Primary Competitors In The Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Read the full oncolytic adenovirus market report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Oncolytic Adenovirus Market?

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncolytic Adenovirus Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company

Companion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Oncolytic Adenovirus Market Between 2026 And 2030?

The oncolytic adenovirus market has demonstrated significant growth in its size over recent years. It is projected to expand from $132.49 billion in 2025 to $143.57 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. This historical expansion can be linked to the emergence of first-generation adenovirus-based therapies, the increasing occurrence of melanoma and prostate cancer, a surge in investment in oncolytic virus research, prompt adoption by cancer research institutes, and strengthening collaborations between biotechnology and academic institutions.

The oncolytic adenovirus market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $195.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this anticipated growth include an escalating demand for engineered adenovirus therapies, their expanding use in treating breast, ovarian, and lung cancers, increased involvement from biotechnology firms, a surge in funding directed towards clinical trials and research and development, and the broadening capacities of hospitals and research institutions in gene therapy. Key trends expected during the forecast timeframe encompass the increasing integration of AI and big data in oncolytic virus research, wider application of genomics and precision medicine in virus engineering, a rise in the utilization of digital platforms for overseeing clinical trials, enhanced automation in the production and quality control of viral agents, and improved IoT-enabled systems for monitoring virus storage and distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Major Drivers Are Influencing Demand In The Oncolytic Adenovirus Market?

The rising occurrence of cancer is projected to fuel the expansion of the oncolytic adenovirus market in the future. Cancer, defined by the unchecked proliferation of cells and their dissemination throughout the body, presents a significant health challenge. This surge in cancer cases stems from an aging global demographic, various lifestyle influences, environmental exposures, inherited genetic susceptibilities, and enhanced diagnostic capabilities. Oncolytic adenovirus offers a promising therapeutic strategy by specifically targeting and eradicating cancer cells, thereby addressing the growing incidence of the disease. For example, data from May 2024 released by the National Cancer Institute (NCI), a US government agency, indicated nearly 20 million new cancer cases and 9.7 million deaths globally, with forecasts for 2040 suggesting an increase to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australian government body, reported that 1.8% of Australians were affected by cancer, with males (2.1%) showing a slightly higher prevalence than females (1.6%), particularly among individuals aged 75 and over. Consequently, the expanding prevalence of cancer is a key factor propelling the oncolytic adenovirus market’s growth.

Which Market Segments Are Examined In The Oncolytic Adenovirus Market Study?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

How Are Trends Transforming The Oncolytic Adenovirus Market Landscape?

Leading entities within the oncolytic adenovirus sector are prioritizing integrated therapeutic approaches, exemplified by VCN-01, where oncolytic virotherapy is paired with chemotherapy to achieve better tumor targeting and elevate treatment effectiveness. VCN-01 is an oncolytic adenovirus designed for selective infection and destruction of malignant cells, concurrently boosting the efficacy of chemotherapy. A notable example occurred in May 2024, when Theriva Biologics, a US-based clinical-stage immuno-oncology company, revealed that the U.S. Food and Drug Administration (FDA) had bestowed Fast Track Designation (FTD) upon its lead candidate, VCN-01. The FTD is applicable to VCN-01 when employed synergistically with gemcitabine and nab-paclitaxel for addressing metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that specifically aims for and multiplies inside tumor cells, assisting in the degradation of the tumor stroma, which represents a significant impediment to successful cancer therapy.

Who Are The Primary Competitors In The Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Read the full oncolytic adenovirus market report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Oncolytic Adenovirus Market?

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncolytic Adenovirus Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company

Companion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Oncolytic Adenovirus Market Between 2026 And 2030?

The oncolytic adenovirus market has demonstrated significant growth in its size over recent years. It is projected to expand from $132.49 billion in 2025 to $143.57 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. This historical expansion can be linked to the emergence of first-generation adenovirus-based therapies, the increasing occurrence of melanoma and prostate cancer, a surge in investment in oncolytic virus research, prompt adoption by cancer research institutes, and strengthening collaborations between biotechnology and academic institutions.

The oncolytic adenovirus market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $195.85 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this anticipated growth include an escalating demand for engineered adenovirus therapies, their expanding use in treating breast, ovarian, and lung cancers, increased involvement from biotechnology firms, a surge in funding directed towards clinical trials and research and development, and the broadening capacities of hospitals and research institutions in gene therapy. Key trends expected during the forecast timeframe encompass the increasing integration of AI and big data in oncolytic virus research, wider application of genomics and precision medicine in virus engineering, a rise in the utilization of digital platforms for overseeing clinical trials, enhanced automation in the production and quality control of viral agents, and improved IoT-enabled systems for monitoring virus storage and distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Major Drivers Are Influencing Demand In The Oncolytic Adenovirus Market?

The rising occurrence of cancer is projected to fuel the expansion of the oncolytic adenovirus market in the future. Cancer, defined by the unchecked proliferation of cells and their dissemination throughout the body, presents a significant health challenge. This surge in cancer cases stems from an aging global demographic, various lifestyle influences, environmental exposures, inherited genetic susceptibilities, and enhanced diagnostic capabilities. Oncolytic adenovirus offers a promising therapeutic strategy by specifically targeting and eradicating cancer cells, thereby addressing the growing incidence of the disease. For example, data from May 2024 released by the National Cancer Institute (NCI), a US government agency, indicated nearly 20 million new cancer cases and 9.7 million deaths globally, with forecasts for 2040 suggesting an increase to 29.9 million cases and 15.3 million deaths. Additionally, in 2023, the Australian Bureau of Statistics, an Australian government body, reported that 1.8% of Australians were affected by cancer, with males (2.1%) showing a slightly higher prevalence than females (1.6%), particularly among individuals aged 75 and over. Consequently, the expanding prevalence of cancer is a key factor propelling the oncolytic adenovirus market’s growth.

Which Market Segments Are Examined In The Oncolytic Adenovirus Market Study?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

How Are Trends Transforming The Oncolytic Adenovirus Market Landscape?

Leading entities within the oncolytic adenovirus sector are prioritizing integrated therapeutic approaches, exemplified by VCN-01, where oncolytic virotherapy is paired with chemotherapy to achieve better tumor targeting and elevate treatment effectiveness. VCN-01 is an oncolytic adenovirus designed for selective infection and destruction of malignant cells, concurrently boosting the efficacy of chemotherapy. A notable example occurred in May 2024, when Theriva Biologics, a US-based clinical-stage immuno-oncology company, revealed that the U.S. Food and Drug Administration (FDA) had bestowed Fast Track Designation (FTD) upon its lead candidate, VCN-01. The FTD is applicable to VCN-01 when employed synergistically with gemcitabine and nab-paclitaxel for addressing metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that specifically aims for and multiplies inside tumor cells, assisting in the degradation of the tumor stroma, which represents a significant impediment to successful cancer therapy.

Who Are The Primary Competitors In The Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Read the full oncolytic adenovirus market report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Oncolytic Adenovirus Market?

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncolytic Adenovirus Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company

Companion Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/companion-diagnostics-global-market-report

Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Clinical Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the oncolytic adenovirus market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Oncolytic Adenovirus Market from 2026 to 2030?

The oncolytic adenovirus market has experienced substantial growth in recent years. It is projected to expand from $132.49 billion in 2025 to $143.57 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. This historical growth can be attributed to several factors, including the development of first-generation adenovirus-based therapies, the increasing prevalence of melanoma and prostate cancer, rising investment in oncolytic virus research, early adoption by cancer research institutes, and growing collaborations between biotech and academic institutions.

The oncolytic adenovirus market is projected to experience substantial expansion over the coming years. This market is forecast to reach $195.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. The anticipated growth during this period is driven by several factors, including the escalating demand for engineered adenovirus treatments, wider use in breast, ovarian, and lung cancer cases, increased involvement from biotechnology firms, greater financial support for clinical trials and research & development, and the enhancement of gene therapy capabilities within hospitals and research institutions. Key trends expected over the forecast horizon involve the growing integration of AI and big data in oncolytic virus investigations, the expanding utilization of genomics and precision medicine in virus engineering, a surge in the deployment of digital platforms for overseeing clinical trials, increasing automation in virus production and quality assurance, and the heightened implementation of IoT-enabled systems for monitoring virus storage and distribution.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21235&type=smp

What Drivers Are Affecting Demand In The Oncolytic Adenovirus Market?

The escalating occurrence of cancer is anticipated to stimulate the future expansion of the oncolytic adenovirus market. Cancer is characterized by unrestrained cell growth and its spread to other body parts. The increasing incidence of cancer is attributed to an aging global population, various lifestyle choices, environmental exposures, genetic predispositions, and advancements in detection methods. Oncolytic adenovirus offers a promising strategy by selectively targeting and eradicating cancer cells to manage the rising cancer rates. For instance, in May 2024, reports from the National Cancer Institute (NCI), a US-based government agency, revealed nearly 20 million new cancer cases and 9.7 million deaths worldwide, with projections for 2040 rising to 29.9 million cases and 15.3 million deaths. Furthermore, in 2023, data from the Australian Bureau of Statistics, an Australia-based government agency, indicated that 1.8% of Australians had cancer, with males (2.1%) being marginally more affected than females (1.6%), especially those aged 75 and over. Thus, the growing incidence of cancer is a key factor driving growth in the oncolytic adenovirus market.

Which Segments Are Gaining Traction In The Oncolytic Adenovirus Market?

The oncolytic adenovirus market covered in this report is segmented –

1) By Virus Type: Adenovirus Type 5-Based Oncolytic Viruses, Adenovirus Type 2-Based Oncolytic Viruses, Other Virus Types

2) By Application: Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Other Applications

3) By End-User: Hospitals, Cancer Research Institutes, Biotechnology Companies, Academic And Research Institutes

Subsegments:

1) By Adenovirus Type 5-Based Oncolytic Viruses: First-Generation Adenovirus Type 5-Based, Second-Generation Adenovirus Type 5-Based, Engineered Adenovirus Type 5-Based

2) By Adenovirus Type 2-Based Oncolytic Viruses: First-Generation Adenovirus Type 2-Based, Second-Generation Adenovirus Type 2-Based, Engineered Adenovirus Type 2-Based

3) By Other Virus Types: Modified Adenovirus Strains, Hybrid Adenovirus Types, Chimeric Adenoviruses

Which Trends Are Guiding The Evolution Of The Oncolytic Adenovirus Market?

Major companies operating in the oncolytic adenovirus market are prioritizing combination therapies, such as VCN-01, which integrates oncolytic virotherapy with chemotherapy to enhance tumor targeting and improve therapeutic outcomes. VCN-01 is an oncolytic adenovirus engineered to specifically infect and destroy cancer cells, concurrently boosting the effectiveness of chemotherapy. For instance, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology company, announced that the U.S. Food and Drug Administration (FDA) has awarded Fast Track Designation (FTD) to its lead candidate, VCN-01. This designation is applicable to VCN-01 when utilized in conjunction with gemcitabine and nab-paclitaxel for the management of metastatic pancreatic adenocarcinoma. VCN-01 is an oncolytic adenovirus that targets and replicates within tumor cells, assisting in the breakdown of the tumor stroma, which represents a key obstacle to effective cancer treatment.

Who Are The Top-Performing Companies In The Oncolytic Adenovirus Market In Recent Years?

Major companies operating in the oncolytic adenovirus market are Amgen Inc., Targovax ASA, CG Oncology Inc., Replimune Group Inc., Imugene Limited, Oncorus Inc., PsiOxus Therapeutics Ltd., Vyriad Inc., Transgene SA, Valo Therapeutics Oy, EpicentRx Inc., DNAtrix Inc., Shanghai Sunway Biotech Co. Ltd., TILT Biotherapeutics Ltd., Oncolys BioPharma Inc., Lokon Pharma AB, GeneMedicine Co. Ltd., Akamis Bio Ltd., Genelux Corporation, SillaJen Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncolytic-adenovirus-global-market-report

How Does The Oncolytic Adenovirus Market Perform Across Major Global Regions?

North America was the largest region in the oncolytic adenovirus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic adenovirus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncolytic Adenovirus Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21235&type=smp

Browse Through More Reports Similar to the Global Oncolytic Adenovirus Market 2026, By The Business Research Company

Viral Hepatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Adeno Associated Viral Vectors Market Report 2026

https://www.thebusinessresearchcompany.com/report/adeno-associated-viral-vectors-global-market-report

Viral Inactivation Market Report 2026

https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model